Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Breast Cancer

Retrieve available abstracts of 370 articles:
HTML format



Single Articles


    November 2024
  1. NASHIMOTO M, Asano Y, Matsui H, Machida Y, et al
    Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.
    Breast Cancer. 2024;31:1010-1017.
    PubMed     Abstract available


  2. YOSHIDA R, Kaneyasu T, Ueki A, Yamauchi H, et al
    High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands.
    Breast Cancer. 2024;31:1028-1036.
    PubMed     Abstract available


    October 2024
  3. TADA H, Miyashita M, Harada-Shoji N, Ebata A, et al
    Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan.
    Breast Cancer. 2024 Oct 28. doi: 10.1007/s12282-024-01639.
    PubMed     Abstract available


  4. WANG X, Zhang X, Zhang L, Meng J, et al
    Clinical outcomes after post-operative radiotherapy for breast cancer patients presenting with ipsilateral supraclavicular metastasis: considerations on the cranial border of irradiation field.
    Breast Cancer. 2024 Oct 23. doi: 10.1007/s12282-024-01644.
    PubMed     Abstract available


  5. TOKUNAGA E, Iwata H, Itoh M, Taira T, et al
    Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
    Breast Cancer. 2024 Oct 8. doi: 10.1007/s12282-024-01640.
    PubMed     Abstract available


  6. HAO J, Remis A, Zhu D, Yao Y, et al
    Mirror therapy for patients with breast cancer: A systematic review and meta-analysis.
    Breast Cancer. 2024 Oct 5. doi: 10.1007/s12282-024-01642.
    PubMed     Abstract available


  7. TAKATORI-SHIRAKAMI Y, Saito M, Yokoyama K
    Economic impact of screening on postdiagnosis work productivity in Japanese women with breast cancer: a life-table modeling approach.
    Breast Cancer. 2024 Oct 4. doi: 10.1007/s12282-024-01637.
    PubMed     Abstract available


  8. KAWAI Y, Nagayama A, Miyao K, Takeuchi M, et al
    A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer.
    Breast Cancer. 2024 Oct 1. doi: 10.1007/s12282-024-01641.
    PubMed     Abstract available


    September 2024
  9. KWON MR, Ko EY, Lee JE, Han BK, et al
    Prediction model for individualized precision surgery in breast cancer patients with complete response on MRI and residual calcifications on mammography after neoadjuvant chemotherapy.
    Breast Cancer. 2024 Sep 30. doi: 10.1007/s12282-024-01638.
    PubMed     Abstract available


  10. HUANG Q, Wang J, Ning H, Liu W, et al
    Integrin beta1 in breast cancer: mechanisms of progression and therapy.
    Breast Cancer. 2024 Sep 30. doi: 10.1007/s12282-024-01635.
    PubMed     Abstract available


  11. MICHAELI JC, Michaeli T, Trapani D, Albers S, et al
    Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
    Breast Cancer. 2024 Sep 25. doi: 10.1007/s12282-024-01634.
    PubMed     Abstract available


  12. ABE T, Kataoka A, Uehiro N, Yoshida N, et al
    Desire for pregnancy and fertility preservation in young patients with breast cancer.
    Breast Cancer. 2024 Sep 25. doi: 10.1007/s12282-024-01633.
    PubMed     Abstract available


  13. ENDO Y, Kotani H, Tamura N, Tanaka K, et al
    Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy.
    Breast Cancer. 2024 Sep 23. doi: 10.1007/s12282-024-01630.
    PubMed     Abstract available


  14. NAKAYAMA T, Niikura N, Yamanaka T, Yamamoto M, et al
    Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
    Breast Cancer. 2024 Sep 20. doi: 10.1007/s12282-024-01632.
    PubMed    


  15. WANG RJ, Liu HY, Guo LF, Yu D, et al
    21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer.
    Breast Cancer. 2024 Sep 19. doi: 10.1007/s12282-024-01636.
    PubMed     Abstract available


  16. JITWATCHARAKOMOL T, Setakornnukul J, Chuthatisith S, Ratanawichitrasin A, et al
    Non-irradiated area of intraoperative radiotherapy with electron technique: outcomes and pattern of failure in early-stage breast cancer from a single-center, registry study.
    Breast Cancer. 2024 Sep 10. doi: 10.1007/s12282-024-01624.
    PubMed     Abstract available


  17. SASADA S, Kumamaru H, Hayashi N, Kinukawa N, et al
    Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese Nationwide Registry.
    Breast Cancer. 2024;31:909-916.
    PubMed     Abstract available


  18. MIYAZAWA K, Satake T, Muto M, Tsunoda Y, et al
    Delayed breast reconstruction with autologous free flap after radiation therapy: vascular complications and aesthetic outcomes.
    Breast Cancer. 2024;31:798-806.
    PubMed     Abstract available


  19. BELLINI C, Pugliese F, Bicchierai G, Amato F, et al
    Contrast-enhanced mammography in the management of breast architectural distortions and avoidance of unnecessary biopsies.
    Breast Cancer. 2024;31:851-857.
    PubMed     Abstract available


  20. SEKI H, Sasada S, Shien T
    Reply to the Letter to the editor "Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?".
    Breast Cancer. 2024 Sep 1. doi: 10.1007/s12282-024-01629.
    PubMed    


    August 2024
  21. CHANG YT, Hong ZJ, Tsai HH, Feng AC, et al
    Hub metastatic gene signature and risk score of breast cancer patients with small tumor sizes using WGCNA.
    Breast Cancer. 2024 Aug 27. doi: 10.1007/s12282-024-01627.
    PubMed     Abstract available


  22. GANATRA H, Tan JK, Simmons A, Bigogno CM, et al
    Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape.
    Breast Cancer. 2024 Aug 27. doi: 10.1007/s12282-024-01628.
    PubMed     Abstract available


  23. KITADAI R, Shimoi T, Yazaki S, Okuma HS, et al
    Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.
    Breast Cancer. 2024 Aug 14. doi: 10.1007/s12282-024-01617.
    PubMed     Abstract available


  24. WATANABE M, Fujiki S, Okura Y, Toshikawa C, et al
    Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community.
    Breast Cancer. 2024 Aug 13. doi: 10.1007/s12282-024-01623.
    PubMed     Abstract available


  25. NAKAYAMA T, Niikura N, Yamanaka T, Yamamoto M, et al
    Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
    Breast Cancer. 2024 Aug 12. doi: 10.1007/s12282-024-01614.
    PubMed     Abstract available


  26. RAHMANI F, Ajoudanifar H, Arbab Soleimani N, Imani Fooladi AA, et al
    Targeted therapies in HER2-positive breast cancer with receptor-redirected Arazyme-linker-Herceptin as a novel fusion protein.
    Breast Cancer. 2024 Aug 9. doi: 10.1007/s12282-024-01625.
    PubMed     Abstract available


  27. RUIZ JI, Lei X, Chi-Fang W, Giordano SH, et al
    Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors.
    Breast Cancer. 2024 Aug 8. doi: 10.1007/s12282-024-01618.
    PubMed     Abstract available


  28. NAKAMURA M, Fujisawa T, Oyoshi H, Zhou Y, et al
    Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC).
    Breast Cancer. 2024 Aug 8. doi: 10.1007/s12282-024-01626.
    PubMed     Abstract available


  29. CHEN YA, Lai HW, Su HC, Loh EW, et al
    Efficacy and safety of adjuvant therapies in older patients with breast cancer: a systematic review and meta-analysis of real-world data.
    Breast Cancer. 2024 Aug 1. doi: 10.1007/s12282-024-01622.
    PubMed     Abstract available


    July 2024
  30. UEZONO H, Onoe T, Shikama N, Ono Y, et al
    Uptake of ultra-hypofractionated radiation therapy following breast-conserving surgery among patients with early-stage breast cancer: a multi-institutional questionnaire survey.
    Breast Cancer. 2024 Jul 24. doi: 10.1007/s12282-024-01621.
    PubMed     Abstract available


  31. ALTUNDAG K
    Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?
    Breast Cancer. 2024 Jul 20. doi: 10.1007/s12282-024-01620.
    PubMed    


  32. HU Z, Lai C, Liu H, Man J, et al
    Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort.
    Breast Cancer. 2024 Jul 19. doi: 10.1007/s12282-024-01619.
    PubMed     Abstract available


  33. SHIBATA A, Tamura N, Kinowaki K, Nishikawa A, et al
    Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.
    Breast Cancer. 2024 Jul 17. doi: 10.1007/s12282-024-01616.
    PubMed     Abstract available


  34. HOSONAGA M, Habano E, Arakawa H, Kaneko K, et al
    Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.
    Breast Cancer. 2024 Jul 17. doi: 10.1007/s12282-024-01612.
    PubMed     Abstract available


  35. PINELLI F, Barbani F, Defilippo B, Fundaro A, et al
    Quality of life in women with breast cancer undergoing neoadjuvant chemotherapy: comparison between PICC and PICC-port.
    Breast Cancer. 2024 Jul 9. doi: 10.1007/s12282-024-01608.
    PubMed     Abstract available


  36. NAKAMOTO S, Iwamoto T, Taira N, Kajiwara Y, et al
    The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10.
    Breast Cancer. 2024 Jul 9. doi: 10.1007/s12282-024-01610.
    PubMed     Abstract available


  37. WEI JF, Li F, Lin JW, Dou ZA, et al
    Development and validation of a neoadjuvant chemotherapy pathological complete remission model based on Reg IV expression in breast cancer tissues: a clinical retrospective study.
    Breast Cancer. 2024 Jul 8. doi: 10.1007/s12282-024-01609.
    PubMed     Abstract available


  38. LUO Y, Chen X, Lv R, Li Q, et al
    Breast-conserving surgery versus modified radical mastectomy in T1-2N3M0 stage breast cancer: a propensity score matching analysis.
    Breast Cancer. 2024 Jul 8. doi: 10.1007/s12282-024-01611.
    PubMed     Abstract available


  39. KOYAMA Y, Nakashima K, Orihara S, Tsunoda H, et al
    Inter- and intra-observer variability of qualitative visual breast-composition assessment in mammography among Japanese physicians: a first multi-institutional observer performance study in Japan.
    Breast Cancer. 2024;31:671-683.
    PubMed     Abstract available


  40. MAITA KC, Avila FR, Torres-Guzman RA, Garcia JP, et al
    The usefulness of artificial intelligence in breast reconstruction: a systematic review.
    Breast Cancer. 2024;31:562-571.
    PubMed     Abstract available


  41. KATO S, Mori H, Saiga M, Watanabe S, et al
    Nipple-areolar complex malposition in breast reconstruction after nipple-sparing mastectomy: a multi-institutional retrospective observational study in Japan.
    Breast Cancer. 2024;31:649-658.
    PubMed     Abstract available


    June 2024
  42. WANG B, Chu H, Wei S, Hsu H, et al
    Exploration of treatment strategies and susceptibility gene of postoperative nausea and vomiting in breast cancer patients: a randomised controlled trial.
    Breast Cancer. 2024 Jun 19. doi: 10.1007/s12282-024-01606.
    PubMed     Abstract available


  43. SEKI H, Ogiya A, Nagura N, Shimo A, et al
    Prognosis of isolated locoregional recurrence after early breast cancer with immediate breast reconstruction surgery: a retrospective multi?institutional study.
    Breast Cancer. 2024 Jun 19. doi: 10.1007/s12282-024-01607.
    PubMed     Abstract available


  44. YAMASHITA T, Sohn JH, Tokunaga E, Niikura N, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
    Breast Cancer. 2024 Jun 17. doi: 10.1007/s12282-024-01600.
    PubMed     Abstract available


  45. HUANG Y, Ke C, Cai J, Wei X, et al
    Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer.
    Breast Cancer. 2024 Jun 15. doi: 10.1007/s12282-024-01605.
    PubMed     Abstract available


  46. TELLI ML, Litton JK, Beck JT, Jones JM, et al
    Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
    Breast Cancer. 2024 Jun 13. doi: 10.1007/s12282-024-01603.
    PubMed     Abstract available


  47. KITANO S, Tsunashima R, Kato C, Watanabe A, et al
    Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer.
    Breast Cancer. 2024 Jun 11. doi: 10.1007/s12282-024-01602.
    PubMed     Abstract available


  48. PURJA S, Nguyen DT, Kim E
    Breast cancer epigenetics: current and evolving treatment.
    Breast Cancer. 2024 Jun 11. doi: 10.1007/s12282-024-01601.
    PubMed     Abstract available


  49. CHEN Y, Zhou Y, Chen J, Yang J, et al
    Exosomal lncRNA SNHG12 promotes angiogenesis and breast cancer progression.
    Breast Cancer. 2024 Jun 4. doi: 10.1007/s12282-024-01574.
    PubMed     Abstract available


    May 2024
  50. MUR-GIMENO E, Coll M, Yuguero-Ortiz A, Navarro M, et al
    Comparison of water- vs. land-based exercise for improving functional capacity and quality of life in patients living with and beyond breast cancer (the AQUA-FiT study): a randomized controlled trial.
    Breast Cancer. 2024 May 30. doi: 10.1007/s12282-024-01596.
    PubMed     Abstract available


  51. TENG L, Du J, Yan S, Xu P, et al
    A novel nomogram and survival analysis for different lymph node status in breast cancer based on the SEER database.
    Breast Cancer. 2024 May 27. doi: 10.1007/s12282-024-01591.
    PubMed     Abstract available


  52. OKUYAMA H, Takada F, Taira N, Nakamura S, et al
    A randomized trial of the impact of symptom monitoring using an electronic patient-reported outcome app on health-related quality of life in postmenopausal breast cancer patients receiving adjuvant endocrine therapy.
    Breast Cancer. 2024 May 26. doi: 10.1007/s12282-024-01592.
    PubMed     Abstract available


  53. KATARIA M, Gupta N, Kumar A, Bhoriwal S, et al
    Assessing the effectiveness of high frequency repetitive transcranial magnetic stimulation for post-mastectomy pain in breast cancer patients: A randomized controlled trial.
    Breast Cancer. 2024 May 26. doi: 10.1007/s12282-024-01598.
    PubMed     Abstract available


  54. FRANCESCHI BT, Bezerra PHA, Torqueti MR
    Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression.
    Breast Cancer. 2024 May 23. doi: 10.1007/s12282-024-01590.
    PubMed     Abstract available


  55. JEZEQUEL P, Lasla H, Gouraud W, Basseville A, et al
    Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
    Breast Cancer. 2024 May 22. doi: 10.1007/s12282-024-01597.
    PubMed     Abstract available


  56. ALTUNDAG K
    Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density.
    Breast Cancer. 2024 May 18. doi: 10.1007/s12282-024-01595.
    PubMed    


  57. DURAN S, Varol U, Tekir O, Soyturk AH, et al
    Resilience's impact on quality of life and post-traumatic growth in breast cancer patients during treatment.
    Breast Cancer. 2024 May 17. doi: 10.1007/s12282-024-01594.
    PubMed     Abstract available


  58. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
    Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
    Breast Cancer. 2024 May 12. doi: 10.1007/s12282-024-01589.
    PubMed    


  59. BAO YQ, Yu TH, Huang W, Mao QF, et al
    Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients.
    Breast Cancer. 2024 May 5. doi: 10.1007/s12282-024-01588.
    PubMed     Abstract available


  60. VAN ROOIJ JAF, Bijkerk E, van der Hulst RRJW, Tuinder SMH, et al
    The influence of a previous implant-based breast reconstruction on postoperative sensation of the deep inferior epigastric artery perforator flap.
    Breast Cancer. 2024;31:456-466.
    PubMed     Abstract available


  61. NOGI H, Ogiya A, Ishitobi M, Yamauchi C, et al
    Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy.
    Breast Cancer. 2024;31:507-518.
    PubMed     Abstract available


  62. CH'NG ES
    Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010-2020.
    Breast Cancer. 2024;31:496-506.
    PubMed     Abstract available


  63. TSUCHIDA Y, Niikura N, Chishima T, Mizuno M, et al
    Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX(R) test data: a retrospective multicenter study in Japan.
    Breast Cancer. 2024;31:401-408.
    PubMed     Abstract available


  64. FUKUI R, Watanabe T, Morimoto K, Fujimoto Y, et al
    Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
    Breast Cancer. 2024;31:536-538.
    PubMed    


    April 2024
  65. SHIMOMURA A, Sagara Y, Koto R, Fujiwara M, et al
    Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.
    Breast Cancer. 2024 Apr 29. doi: 10.1007/s12282-024-01572.
    PubMed     Abstract available


  66. KAWAMOTO H, Tsugawa K, Furuya Y, Sakamaki K, et al
    Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan.
    Breast Cancer. 2024 Apr 27. doi: 10.1007/s12282-024-01584.
    PubMed     Abstract available


  67. LEE SJ, Cha CD, Hong H, Choi YY, et al
    Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2024 Apr 27. doi: 10.1007/s12282-024-01586.
    PubMed     Abstract available


  68. YANG PJ, Tsai EM, Hou MF, Lee YJ, et al
    Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors.
    Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01579.
    PubMed     Abstract available


  69. YOSHINAMI T
    Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy.
    Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01571.
    PubMed     Abstract available


  70. ALTUNDAG K
    Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients.
    Breast Cancer. 2024 Apr 22. doi: 10.1007/s12282-024-01587.
    PubMed    


  71. SHANG Y, Wang X, Liu Y, Cheng W, et al
    Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database.
    Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01583.
    PubMed     Abstract available


  72. NA S, Kim M, Park Y, Kwon HJ, et al
    Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.
    Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01585.
    PubMed     Abstract available


  73. YOSHINAMI T, Nagai SE, Hattori M, Okamura T, et al
    Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or seco
    Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575.
    PubMed     Abstract available


  74. ROUSSET-JABLONSKI C, Lortal B, Lantheaume S, Arnould L, et al
    French national survey on breast cancer care: caregiver and patient views.
    Breast Cancer. 2024 Apr 18. doi: 10.1007/s12282-024-01576.
    PubMed     Abstract available


  75. ZHANG HP, Jiang RY, Zhu JY, Sun KN, et al
    PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
    Breast Cancer. 2024 Apr 17. doi: 10.1007/s12282-024-01567.
    PubMed     Abstract available


  76. TOKUDA PJK, Mitsuyoshi T, Ono Y, Kishi T, et al
    Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
    Breast Cancer. 2024 Apr 12. doi: 10.1007/s12282-024-01577.
    PubMed     Abstract available


  77. DE MOURA A, Loirat D, Vaillant S, Korbi S, et al
    Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    Breast Cancer. 2024 Apr 10. doi: 10.1007/s12282-024-01565.
    PubMed     Abstract available


  78. SUZUKI K, Morishita S, Nakano J, Okayama T, et al
    Association between quality of life and mortality risk in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2024 Apr 9. doi: 10.1007/s12282-024-01581.
    PubMed     Abstract available


  79. WATANABE A, Tsunashima R, Kato C, Kitano S, et al
    Investigation of recurrence prediction ability of EndoPredict((R)) using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict((R)) from microarray data from fresh-frozen to FFPE
    Breast Cancer. 2024 Apr 8. doi: 10.1007/s12282-024-01573.
    PubMed     Abstract available


  80. YOSHIMURA M, Yamauchi C, Sanuki N, Hamamoto Y, et al
    The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition.
    Breast Cancer. 2024 Apr 5. doi: 10.1007/s12282-024-01568.
    PubMed     Abstract available


  81. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
    The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
    Breast Cancer. 2024 Apr 3. doi: 10.1007/s12282-024-01566.
    PubMed     Abstract available


  82. LIN D, Sturgeon KM, Muscat JE, Zhou S, et al
    Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
    Breast Cancer. 2024 Apr 2. doi: 10.1007/s12282-024-01569.
    PubMed     Abstract available


  83. YE JH, Yu J, Huang MY, Mo YM, et al
    The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
    Breast Cancer. 2024 Apr 1. doi: 10.1007/s12282-024-01553.
    PubMed     Abstract available


    March 2024
  84. OCHIYA T, Hashimoto K, Shimomura A
    Prospects for liquid biopsy using microRNA and extracellular vesicles in breast cancer.
    Breast Cancer. 2024 Mar 30. doi: 10.1007/s12282-024-01563.
    PubMed     Abstract available


  85. NARUI K, Satake T, Ishikawa T, Muto M, et al
    Endoscopic mastectomy followed by immediate breast reconstruction with fat grafting for breast cancer.
    Breast Cancer. 2024 Mar 21. doi: 10.1007/s12282-024-01561.
    PubMed     Abstract available


  86. HASHIMOTO K, Ochiya T, Shimomura A
    Liquid biopsy using non-coding RNAs and extracellular vesicles for breast cancer management.
    Breast Cancer. 2024 Mar 21. doi: 10.1007/s12282-024-01562.
    PubMed     Abstract available


  87. VO K, Ladbury C, Yoon S, Bazan J, et al
    Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.
    Breast Cancer. 2024 Mar 20. doi: 10.1007/s12282-024-01560.
    PubMed     Abstract available


  88. OHMURA H, Hanamura F, Okumura Y, Ando Y, et al
    Liquid biopsy for breast cancer and other solid tumors: a review of recent advances.
    Breast Cancer. 2024 Mar 16. doi: 10.1007/s12282-024-01556.
    PubMed     Abstract available


  89. HU X
    The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
    Breast Cancer. 2024 Mar 14. doi: 10.1007/s12282-024-01557.
    PubMed     Abstract available


  90. LI G, Lin X, Wang X, Cai L, et al
    Enhancing radiosensitivity in triple-negative breast cancer through targeting ELOB.
    Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01554.
    PubMed     Abstract available


  91. KANG D, Park S, Kim HJ, Lee J, et al
    Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile.
    Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01559.
    PubMed     Abstract available


  92. KIDA K, Yamada A, Shimada K, Narui K, et al
    A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
    Breast Cancer. 2024 Mar 8. doi: 10.1007/s12282-024-01551.
    PubMed     Abstract available


  93. OBA K, Adachi M, Kobayashi T, Takaya E, et al
    Deep learning model to predict Ki-67 expression of breast cancer using digital breast tomosynthesis.
    Breast Cancer. 2024 Mar 7. doi: 10.1007/s12282-024-01549.
    PubMed     Abstract available


  94. HATTORI M, Honma N, Nagai S, Narui K, et al
    Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
    Breast Cancer. 2024 Mar 4. doi: 10.1007/s12282-024-01550.
    PubMed     Abstract available


  95. KASAHARA M, Kanematsu S, Tanaka Y, Okazaki S, et al
    Clinical benefits of tomosynthesis-guided vacuum assisted breast biopsy: a comparison with stereotactic vacuum assisted biopsy.
    Breast Cancer. 2024;31:329-334.
    PubMed     Abstract available


  96. WU X, Gui Y, Liu J, Li S, et al
    Patient-reported outcomes of mesh in minimally invasive (laparoscopic/robot-assisted) immediate subpectoral prosthesis breast reconstruction: a retrospective study.
    Breast Cancer. 2024;31:243-251.
    PubMed     Abstract available


  97. WONG HH, Cojocaru E, Watkins J, James S, et al
    Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.
    Breast Cancer. 2024;31:272-282.
    PubMed     Abstract available


  98. AOYAMA Y, Hoshino E, Shimomura A, Shimizu C, et al
    Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.
    Breast Cancer. 2024;31:234-242.
    PubMed     Abstract available


  99. CHEN BF, Tsai YF, Lien PJ, Lin YS, et al
    Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
    Breast Cancer. 2024;31:217-227.
    PubMed     Abstract available


  100. NAKAMURA A, Ohnuki K, Takahashi H, Usami S, et al
    The effects of breast density on the benefits of mammograms with adjunctive ultrasonography in breast screening.
    Breast Cancer. 2024;31:228-233.
    PubMed     Abstract available


    February 2024
  101. PARIJA M, Prakash S, Krishna BM, Dash S, et al
    SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor beta.
    Breast Cancer. 2024 Feb 29. doi: 10.1007/s12282-024-01555.
    PubMed     Abstract available


  102. KIM N, Cho WK, Park W, Lee JE, et al
    Outcomes of whole breast radiation therapy in Asian breast cancer patients with prior cosmetic implants.
    Breast Cancer. 2024 Feb 18. doi: 10.1007/s12282-024-01547.
    PubMed     Abstract available


  103. SATO K, Fuchikami H, Takeda N, Natsume N, et al
    Preliminary report on ultrashort perioperative partial-breast irradiation with multicatheter interstitial brachytherapy for early-stage breast cancer.
    Breast Cancer. 2024 Feb 15. doi: 10.1007/s12282-024-01546.
    PubMed     Abstract available


  104. HACKING SM, Windsor G, Cooper R, Jiao Z, et al
    A novel approach correlating pathologic complete response with digital pathology and radiomics in triple-negative breast cancer.
    Breast Cancer. 2024 Feb 13. doi: 10.1007/s12282-024-01544.
    PubMed     Abstract available


  105. IWAMOTO T, Kumamaru H, Niikura N, Sagara Y, et al
    Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.
    Breast Cancer. 2024 Feb 6. doi: 10.1007/s12282-024-01545.
    PubMed     Abstract available


  106. YU T, Rui L, Jiumei Z, Ziwei L, et al
    Advances in the study of autophagy in breast cancer.
    Breast Cancer. 2024 Feb 5. doi: 10.1007/s12282-023-01541.
    PubMed     Abstract available


  107. ZHUANG JY, Huang ZN, Weng ZJ, Liu MM, et al
    Expression and clinical significance of hypoxia-induced long non-coding RNA TCONS_I2_00001955 in breast cancer.
    Breast Cancer. 2024 Feb 4. doi: 10.1007/s12282-023-01540.
    PubMed     Abstract available


    January 2024
  108. ZHENG H, Wu L, Chen J, Na N, et al
    Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models.
    Breast Cancer. 2024 Jan 30. doi: 10.1007/s12282-024-01543.
    PubMed     Abstract available


  109. HOSHI N, Uemura T, Tachibana K, Abe S, et al
    Endosomal protein expression of gamma1-adaptin is associated with tumor growth activity and relapse-free survival in breast cancer.
    Breast Cancer. 2024 Jan 24. doi: 10.1007/s12282-023-01539.
    PubMed     Abstract available


  110. DING W, Ye D, Chen H, Lin Y, et al
    Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.
    Breast Cancer. 2024 Jan 17. doi: 10.1007/s12282-023-01538.
    PubMed     Abstract available


  111. SAGARA Y, Kumamaru H, Niikura N, Miyashita M, et al
    2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
    Breast Cancer. 2024 Jan 5. doi: 10.1007/s12282-023-01532.
    PubMed     Abstract available


  112. TAIRA N, Kikawa Y, Iwamoto T, Miyoshi Y, et al
    Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.
    Breast Cancer. 2024 Jan 4. doi: 10.1007/s12282-023-01537.
    PubMed     Abstract available


  113. HORIMOTO Y
    Comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
    Breast Cancer. 2024;31:154.
    PubMed     Abstract available


  114. YOSHIDA M, Yoshimura RI, Notake R, Shinjo H, et al
    Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study.
    Breast Cancer. 2024;31:75-83.
    PubMed     Abstract available


    December 2023
  115. HONG YW, Kuo IM, Kuo WL, Yu CC, et al
    The influence of chronic renal insufficiency on multi-therapeutic modalities for breast cancer: a single-center experience.
    Breast Cancer. 2023 Dec 27. doi: 10.1007/s12282-023-01530.
    PubMed     Abstract available


  116. KAWAI M, Ohtani S, Iwasaki M, Yamamoto S, et al
    The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition.
    Breast Cancer. 2023 Dec 26. doi: 10.1007/s12282-023-01531.
    PubMed     Abstract available


  117. KAZEMZADEH F, Snoek JAA, Voorham QJ, van Oijen MGH, et al
    Association of metastatic pattern in breast cancer with tumor and patient-specific factors: a nationwide autopsy study using artificial intelligence.
    Breast Cancer. 2023 Dec 22. doi: 10.1007/s12282-023-01534.
    PubMed     Abstract available


  118. KUBOTA K, Nakashima K, Nakashima K, Kataoka M, et al
    Correction: The Japanese breast cancer society clinical practice guidelines for breast cancer screening and diagnosis, 2022 edition.
    Breast Cancer. 2023 Dec 11. doi: 10.1007/s12282-023-01533.
    PubMed    


  119. ALTUNDAG K
    Are breast cancer subtypes different in breast cancer patients with and without hepatitis C virus infection?
    Breast Cancer. 2023 Dec 9. doi: 10.1007/s12282-023-01536.
    PubMed    


  120. MIYASHITA M, Kumamaru H, Niikura N, Sagara Y, et al
    Annual report of the Japanese Breast Cancer Registry for 2019.
    Breast Cancer. 2023 Dec 4. doi: 10.1007/s12282-023-01526.
    PubMed     Abstract available


  121. TANG Z, Li L, Huang X, Zhao Y, et al
    Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database.
    Breast Cancer. 2023 Dec 3. doi: 10.1007/s12282-023-01523.
    PubMed     Abstract available


    November 2023
  122. IESATO A, Fushimi A, Tahara R, Terada M, et al
    A novel system to provide information via online YouTube videos and an evaluation of current online information about hereditary breast cancer.
    Breast Cancer. 2023 Nov 23. doi: 10.1007/s12282-023-01512.
    PubMed     Abstract available


  123. NISHIKAWA Y, Agatsuma N, Utsumi T, Funakoshi T, et al
    Medical care costs according to the stage and subtype of breast cancer in a municipal setting: a case study of Hachioji City, Japan.
    Breast Cancer. 2023 Nov 20. doi: 10.1007/s12282-023-01517.
    PubMed     Abstract available


  124. JING R, Bai S, Zhang P, Ren H, et al
    IDO-1 impairs antitumor immunity of natural killer cells in triple-negative breast cancer via up-regulation of HLA-G.
    Breast Cancer. 2023 Nov 19. doi: 10.1007/s12282-023-01522.
    PubMed     Abstract available


  125. FATHY A, Abdelrazek MA, Attallah AM, Abouzid A, et al
    Hepatitis C virus may accelerate breast cancer progression by increasing mutant p53 and c-Myc oncoproteins circulating levels.
    Breast Cancer. 2023 Nov 16. doi: 10.1007/s12282-023-01519.
    PubMed     Abstract available


  126. KUBOTA K, Nakashima K, Nakashima K, Kataoka M, et al
    The Japanese breast cancer society clinical practice guidelines for breast cancer screening and diagnosis, 2022 edition.
    Breast Cancer. 2023 Nov 16. doi: 10.1007/s12282-023-01521.
    PubMed     Abstract available


  127. PELZER F, Troger W, Reif M, Schonberg S, et al
    Fatigue and quality of life during neoadjuvant chemotherapy of early breast cancer: a prospective multicenter cohort study.
    Breast Cancer. 2023 Nov 15. doi: 10.1007/s12282-023-01520.
    PubMed     Abstract available


  128. PAPPOT H, Bjornsson BP, Krause O, Baeksted C, et al
    Machine learning applied in patient-reported outcome research-exploring symptoms in adjuvant treatment of breast cancer.
    Breast Cancer. 2023 Nov 8. doi: 10.1007/s12282-023-01515.
    PubMed     Abstract available


  129. HONMA N, Yoshida M, Kinowaki K, Horii R, et al
    The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition.
    Breast Cancer. 2023 Nov 7. doi: 10.1007/s12282-023-01518.
    PubMed    


  130. SHEN X, Wang G, He H, Shang P, et al
    SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer.
    Breast Cancer. 2023 Nov 2. doi: 10.1007/s12282-023-01516.
    PubMed     Abstract available


  131. WILLIAMSON M, Press DJ, Hansen SA, Tomar A, et al
    Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
    Breast Cancer. 2023 Nov 1. doi: 10.1007/s12282-023-01514.
    PubMed     Abstract available


  132. TERANAKA R, Fujimoto H, Masuda T, Kuroda M, et al
    Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models.
    Breast Cancer. 2023;30:1018-1027.
    PubMed     Abstract available


  133. PAN J, Peng L, Tong X, Chen X, et al
    Prognosis of post-neoadjuvant therapy patients who underwent immediate breast reconstruction: a SEER-based, propensity-matched study.
    Breast Cancer. 2023;30:986-996.
    PubMed     Abstract available


  134. COLDITZ C, Keinki C, Huebner J
    Self-help management of patients undergoing chemotherapy: analysis of the online forum of the women's self-help association against cancer.
    Breast Cancer. 2023;30:926-932.
    PubMed     Abstract available


    October 2023
  135. TAKAHASHI M, Osako T, Yasojima H, Inoue K, et al
    Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.
    Breast Cancer. 2023 Oct 26. doi: 10.1007/s12282-023-01511.
    PubMed     Abstract available


  136. SAKAI T, Kutomi G, Shien T, Asaga S, et al
    The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition.
    Breast Cancer. 2023 Oct 16. doi: 10.1007/s12282-023-01510.
    PubMed     Abstract available


  137. KONG L, Yang Z, Zheng C, Lu T, et al
    Psychometric evaluation of the Chinese version of the breast cancer perception scale for community women: a translation and validation study.
    Breast Cancer. 2023 Oct 13. doi: 10.1007/s12282-023-01508.
    PubMed     Abstract available


  138. UEMATSU T
    Rethinking screening mammography in Japan: next-generation breast cancer screening through breast awareness and supplemental ultrasonography.
    Breast Cancer. 2023 Oct 12. doi: 10.1007/s12282-023-01506.
    PubMed     Abstract available


  139. FUJIKI Y, Kashiwaba M, Sato M, Kawano J, et al
    Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
    Breast Cancer. 2023 Oct 9. doi: 10.1007/s12282-023-01509.
    PubMed     Abstract available


  140. TERADA M, Ito A, Kikawa Y, Koizumi K, et al
    The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
    Breast Cancer. 2023 Oct 7. doi: 10.1007/s12282-023-01505.
    PubMed     Abstract available


  141. SUZUKI K, Ohe R, Kabasawa T, Kitaoka T, et al
    Histological spatial analysis on the induction of PD-L1(+) macrophages by CD8(+) T cells at the marginal microenvironment of triple-negative breast cancer.
    Breast Cancer. 2023 Oct 4. doi: 10.1007/s12282-023-01507.
    PubMed     Abstract available


  142. KUSAMA H, Kittaka N, Soma A, Taniguchi A, et al
    Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer.
    Breast Cancer. 2023 Oct 2. doi: 10.1007/s12282-023-01504.
    PubMed     Abstract available


    September 2023
  143. PATIL PB, Patel JK
    Preparation, characterization, and in vitro cytotoxicity activity of allyl-isothiocyanate-embedded polymeric nanoparticles for potential breast cancer targeting.
    Breast Cancer. 2023 Sep 11. doi: 10.1007/s12282-023-01501.
    PubMed     Abstract available


  144. VIDULA N, Yau C, Rugo HS
    Glutaminase (GLS1) gene expression in primary breast cancer.
    Breast Cancer. 2023 Sep 7. doi: 10.1007/s12282-023-01502.
    PubMed     Abstract available


  145. VOLLBACH FH, Neuss C, Siegwart LC, Bigdeli AK, et al
    The transverse myocutaneous gracilis flap (TMG) for breast reconstruction: ipsi vs. contralateral harvest-aesthetic outcome and refinement procedures.
    Breast Cancer. 2023;30:845-855.
    PubMed     Abstract available


  146. GHILLI M, Mariniello MD, Ferre F, Morganti R, et al
    Quality of life and satisfaction of patients after oncoplastic or traditional breast-conserving surgery using the BREAST-Q (BCT module): a prospective study.
    Breast Cancer. 2023;30:802-809.
    PubMed     Abstract available


  147. TAKEHARA Y, Matsuda N, Kobayashi D, Yoshida A, et al
    Radiation-induced angiosarcoma of the breast: individual participant meta-analysis of Japanese population.
    Breast Cancer. 2023;30:739-747.
    PubMed     Abstract available


  148. FUKUI R, Watanabe T, Morimoto K, Fujimoto Y, et al
    An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
    Breast Cancer. 2023;30:703-713.
    PubMed     Abstract available


    August 2023
  149. DONG H, Yang C, Chen X, Sun H, et al
    Breast cancer-derived exosomal lncRNA SNHG14 induces normal fibroblast activation to cancer-associated fibroblasts via the EBF1/FAM171A1 axis.
    Breast Cancer. 2023 Aug 31. doi: 10.1007/s12282-023-01496.
    PubMed     Abstract available


  150. SANUKI F, Mikami Y, Nishimura H, Fujita Y, et al
    Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
    Breast Cancer. 2023 Aug 29. doi: 10.1007/s12282-023-01498.
    PubMed     Abstract available


  151. MURATA T, Yoshida M, Shiino S, Watase C, et al
    Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer.
    Breast Cancer. 2023 Aug 23. doi: 10.1007/s12282-023-01500.
    PubMed     Abstract available


  152. OHSUMI S
    Reply to "Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?".
    Breast Cancer. 2023 Aug 21. doi: 10.1007/s12282-023-01495.
    PubMed    


  153. OEI SL, Thronicke A, Grieb G, Schad F, et al
    Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data.
    Breast Cancer. 2023 Aug 16. doi: 10.1007/s12282-023-01494.
    PubMed     Abstract available


  154. JHANGIANI N, Philip M, Jatoi I
    Breast cancer screening guidelines: discrepancies raise concerns about validity.
    Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01493.
    PubMed    


  155. AKSHAYA RL, Saranya I, Selvamurugan N
    MicroRNAs mediated interaction of tumor microenvironment cells with breast cancer cells during bone metastasis.
    Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01491.
    PubMed     Abstract available


  156. ILIE SM, Briot N, Constantin G, Roussot N, et al
    Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer. 2023 Aug 10. doi: 10.1007/s12282-023-01490.
    PubMed     Abstract available


    July 2023
  157. CHEN ST, Lai HW, Chang JH, Liao CY, et al
    Diagnostic accuracy of pre-operative breast magnetic resonance imaging (MRI) in predicting axillary lymph node metastasis: variations in intrinsic subtypes, and strategy to improve negative predictive value-an analysis of 2473 invasive breast cancer p
    Breast Cancer. 2023 Jul 27. doi: 10.1007/s12282-023-01488.
    PubMed     Abstract available


  158. KAWAMURA C, Iwagami M, Sun Y, Komiyama J, et al
    Factors associated with non-participation in breast cancer screening: analysis of the 2016 and 2019 comprehensive survey of living conditions in Japan.
    Breast Cancer. 2023 Jul 25. doi: 10.1007/s12282-023-01486.
    PubMed     Abstract available


  159. FUTAMURA M, Nakayama T, Yoshinami T, Oshiro C, et al
    Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Breast Cancer. 2023 Jul 24. doi: 10.1007/s12282-023-01485.
    PubMed     Abstract available


  160. JESUS OJ, Luis CP, Matilde MF
    Effects of exercise on cancer-related cognitive impairment in breast cancer survivors: a scoping review.
    Breast Cancer. 2023 Jul 22. doi: 10.1007/s12282-023-01484.
    PubMed     Abstract available


  161. LI C, Yuan Q, Deng T, Xu G, et al
    Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2023 Jul 20. doi: 10.1007/s12282-023-01487.
    PubMed     Abstract available


  162. JIANG T, Chen J, Wang Z, Wang X, et al
    miR-4796 enhances the sensitivity of breast cancer cells to ionising radiation by impairing the DNA repair pathway.
    Breast Cancer. 2023 Jul 17. doi: 10.1007/s12282-023-01482.
    PubMed     Abstract available


  163. MORIKAWA H, Oba T, Kiyosawa N, Iji R, et al
    Significance of skeletal muscle index-to-body mass index ratio as a predictor of post-surgical bleeding after mastectomy in patients with breast cancer.
    Breast Cancer. 2023 Jul 13. doi: 10.1007/s12282-023-01483.
    PubMed     Abstract available


  164. SUZUKI Y, Iwamoto T, Uno M, Hatono M, et al
    Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
    Breast Cancer. 2023 Jul 8. doi: 10.1007/s12282-023-01480.
    PubMed     Abstract available


  165. SAEKI S, Iwatani T, Kitano A, Sakurai N, et al
    Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.
    Breast Cancer. 2023 Jul 3. doi: 10.1007/s12282-023-01479.
    PubMed    


  166. LI L, Yang W, Jia D, Zheng S, et al
    Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.
    Breast Cancer. 2023;30:666-684.
    PubMed     Abstract available


  167. WATANABE J, Kataoka Y, Koike A, Miki A, et al
    Efficacy and safety of surgical energy devices for axillary node dissection: a systematic review and network meta-analysis.
    Breast Cancer. 2023;30:531-540.
    PubMed     Abstract available


  168. KAWAGUCHI S, Kinowaki K, Tamura N, Masumoto T, et al
    High-accuracy prediction of axillary lymph node metastasis in invasive lobular carcinoma using focal cortical thickening on magnetic resonance imaging.
    Breast Cancer. 2023;30:637-646.
    PubMed     Abstract available


  169. MARINIELLO MD, Ghilli M, Favati B, Gerges I, et al
    Cell-free biomimetic polyurethane-based scaffold for breast reconstruction following non-malignant lesion resection. A first-in-human study.
    Breast Cancer. 2023;30:559-569.
    PubMed     Abstract available


  170. OIWA M, Suda N, Morita T, Takahashi Y, et al
    Validity of computed mean compressed fibroglandular tissue thickness and breast composition for stratification of masking risk in Japanese women.
    Breast Cancer. 2023;30:541-551.
    PubMed     Abstract available


  171. KIKUCHI M, Gomi N, Ueki A, Osako T, et al
    Effectiveness and tasks of breast MRI surveillance for high-risk women with cancer susceptibility genes other than BRCA1/2: a single institution study.
    Breast Cancer. 2023;30:577-583.
    PubMed     Abstract available


  172. FERNANDO H, Noelia G, Maria E, Pedro M, et al
    Centrally located breast carcinomas treated with central quadrantectomy and immediate nipple-areola reconstruction: a cohort study.
    Breast Cancer. 2023;30:552-558.
    PubMed     Abstract available


    June 2023
  173. KUTHETHUR R, Jerome MS, Subbannayya Y, Chakrabarty S, et al
    An integrated analysis of microRNAs regulating DNA damage response in triple-negative breast cancer.
    Breast Cancer. 2023 Jun 21. doi: 10.1007/s12282-023-01477.
    PubMed     Abstract available


  174. YIN M, Gu K, Cai H, Shu XO, et al
    Association between chronic pain and quality of life in long-term breast cancer survivors: a prospective analysis.
    Breast Cancer. 2023 Jun 17. doi: 10.1007/s12282-023-01472.
    PubMed     Abstract available


  175. RAINONE M, Behrendt CE, Kasparian S, Nguyen T, et al
    HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia.
    Breast Cancer. 2023 Jun 16. doi: 10.1007/s12282-023-01473.
    PubMed     Abstract available


  176. SAEKI S, Iwatani T, Kitano A, Sakurai N, et al
    Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.
    Breast Cancer. 2023 Jun 13. doi: 10.1007/s12282-023-01476.
    PubMed     Abstract available


  177. YUSOF KM, Mohd Sidik S, Mahmud R, Abdullah M, et al
    Association of psychological distress with arm morbidity symptoms in breast cancer survivors: outcomes from the use of PHQ-9 and GAD-7 questionnaires.
    Breast Cancer. 2023 Jun 12. doi: 10.1007/s12282-023-01475.
    PubMed     Abstract available


  178. VAN BEKKUM S, Clarijs ME, van der Veen FJC, van Rosmalen J, et al
    What affects women's decision-making on breast reconstruction after mastectomy for breast cancer?
    Breast Cancer. 2023 Jun 12. doi: 10.1007/s12282-023-01471.
    PubMed     Abstract available


    May 2023
  179. ABDOLLAHI E, Mozdarani H, Alizadeh BZ
    Role of circ-FOXO3 and miR-23a in radiosensitivity of breast cancer.
    Breast Cancer. 2023 May 24. doi: 10.1007/s12282-023-01463.
    PubMed     Abstract available


  180. NOZAWA K, Terada M, Onishi M, Ozaki Y, et al
    Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
    Breast Cancer. 2023 May 22. doi: 10.1007/s12282-023-01461.
    PubMed     Abstract available


  181. LIN L, Pfender K, Ditsch N, Kuhn C, et al
    KLF11 is an independent negative prognostic factor for breast cancer from a cohort study and induces proliferation and inhibits apoptosis in vitro.
    Breast Cancer. 2023 May 18. doi: 10.1007/s12282-023-01470.
    PubMed     Abstract available


  182. KHALID F, Takagi K, Sato A, Yamaguchi M, et al
    Interleukin (IL)-17A in triple-negative breast cancer: a potent prognostic factor associated with intratumoral neutrophil infiltration.
    Breast Cancer. 2023 May 13. doi: 10.1007/s12282-023-01467.
    PubMed     Abstract available


  183. YAMAUCHI H, Toi M, Takayama S, Nakamura S, et al
    Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 May 12. doi: 10.1007/s12282-023-01468.
    PubMed    


  184. SAKAMOTO T, Tanimoto K, Eguchi H, Sasaki S, et al
    Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells.
    Breast Cancer. 2023 May 11. doi: 10.1007/s12282-023-01465.
    PubMed     Abstract available


  185. ALTUNDAG K
    Is there any association between acute kidney injury and olaparib use in patients with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 May 11. doi: 10.1007/s12282-023-01469.
    PubMed    


  186. ALTUNDAG K
    Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?
    Breast Cancer. 2023 May 4. doi: 10.1007/s12282-023-01464.
    PubMed    


  187. PATHAK R, Leslie M, Dondapati P, Davis R, et al
    Increased breast cancer mortality due to treatment delay and needle biopsy type: a retrospective analysis of SEER-medicare.
    Breast Cancer. 2023 May 3. doi: 10.1007/s12282-023-01456.
    PubMed     Abstract available


  188. LI JJ, Yu Y, Ge J
    HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Breast Cancer. 2023;30:364-378.
    PubMed     Abstract available


    April 2023
  189. TOMIOKA N, Hatanaka KC, Okuyama D, Watanabe KI, et al
    Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Breast Cancer. 2023 Apr 27. doi: 10.1007/s12282-023-01454.
    PubMed    


  190. JIAO Y, Guo X, Lv Q
    Options of locoregional therapy for primary foci of breast cancer influence the rate of nonregional lymph node metastasis in N2-N3 status patients: a SEER database analysis.
    Breast Cancer. 2023 Apr 27. doi: 10.1007/s12282-023-01459.
    PubMed     Abstract available


  191. OHSUMI S, Watanabe K, Kondo N, Kosaka Y, et al
    Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry.
    Breast Cancer. 2023 Apr 17. doi: 10.1007/s12282-023-01452.
    PubMed     Abstract available


  192. NOMURA T, Kawai M, Fukuma Y, Koike Y, et al
    Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition.
    Breast Cancer. 2023 Apr 8. doi: 10.1007/s12282-023-01455.
    PubMed     Abstract available


  193. YAMAUCHI H, Toi M, Takayama S, Nakamura S, et al
    Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 Apr 1. doi: 10.1007/s12282-023-01451.
    PubMed     Abstract available


    March 2023
  194. TAMURA K, Mukohara T, Yonemori K, Kawabata Y, et al
    Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).
    Breast Cancer. 2023 Mar 29. doi: 10.1007/s12282-023-01443.
    PubMed     Abstract available


  195. AKYOL M, Tugral A, Aribas Z, Bakar Y, et al
    Assessment of the cardiorespiratory fitness and the quality of life of patients with breast cancer undergoing chemotherapy: a prospective study.
    Breast Cancer. 2023 Mar 23. doi: 10.1007/s12282-023-01453.
    PubMed     Abstract available


  196. SOWA Y, Inafuku N, Tsuge I, Yamanaka H, et al
    Development and implementation of a decision aid for post-mastectomy breast reconstruction for Japanese women with breast cancer: a field-testing study.
    Breast Cancer. 2023 Mar 18. doi: 10.1007/s12282-023-01447.
    PubMed     Abstract available


  197. NAGAHASHI M, Ling Y, Toshikawa C, Hayashida T, et al
    Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
    Breast Cancer. 2023 Mar 17. doi: 10.1007/s12282-023-01449.
    PubMed     Abstract available


  198. JINBO K, Fujita T, Kasahara R, Jinbo R, et al
    The effect of combined risk factors on breast cancer-related lymphedema: a study using decision trees.
    Breast Cancer. 2023 Mar 14. doi: 10.1007/s12282-023-01450.
    PubMed     Abstract available


  199. TOMIOKA N, Hatanaka KC, Okuyama D, Watanabe KI, et al
    Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Breast Cancer. 2023 Mar 9. doi: 10.1007/s12282-023-01442.
    PubMed     Abstract available


  200. SONG C, Kendi AT, Shim JY, Jung D, et al
    ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
    Breast Cancer. 2023 Mar 1. doi: 10.1007/s12282-023-01437.
    PubMed     Abstract available


  201. WANG F, Fang L, Fu B, Fan C, et al
    Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes.
    Breast Cancer. 2023 Mar 1. doi: 10.1007/s12282-023-01440.
    PubMed     Abstract available


  202. YAMAKADO R, Ishitobi M, Kondo N, Yamauchi C, et al
    Physicians' perception about the impact of breast reconstruction on patient prognosis: a survey in Japan.
    Breast Cancer. 2023;30:302-308.
    PubMed     Abstract available


  203. KWON MR, Chang Y, Park B, Ryu S, et al
    Performance analysis of screening mammography in Asian women under 40 years.
    Breast Cancer. 2023;30:241-248.
    PubMed     Abstract available


  204. KONARA MUDIYANSELAGE SP, Wu YL, Kukreti S, Chen CC, et al
    Dynamic changes in quality of life, psychological status, and body image in women who underwent a mastectomy as compared with breast reconstruction: an 8-year follow up.
    Breast Cancer. 2023;30:226-240.
    PubMed     Abstract available


    February 2023
  205. ZHANG H, Barner JC, Moczygemba LR, Rascati KL, et al
    Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis.
    Breast Cancer. 2023 Feb 26. doi: 10.1007/s12282-023-01441.
    PubMed     Abstract available


  206. KOU K, Cameron J, Youl P, Pyke C, et al
    Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study.
    Breast Cancer. 2023 Feb 21. doi: 10.1007/s12282-023-01439.
    PubMed     Abstract available


  207. JIANG F, Yang L, Jiao X
    Dynamic network biomarker to determine the critical point of breast cancer stage progression.
    Breast Cancer. 2023 Feb 18. doi: 10.1007/s12282-023-01438.
    PubMed     Abstract available


  208. QING X, Yuan C, Wang K
    Characterization of protein-based risk signature to predict prognosis and evaluate the tumor immune environment in breast cancer.
    Breast Cancer. 2023 Feb 2. doi: 10.1007/s12282-023-01435.
    PubMed     Abstract available


    January 2023
  209. KADA MOHAMMED S, Billa O, Ladoire S, Jankowski C, et al
    HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.
    Breast Cancer. 2023 Jan 30. doi: 10.1007/s12282-022-01432.
    PubMed     Abstract available


  210. IMOTO S, Wang K, Bi XW, Liu G, et al
    Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
    Breast Cancer. 2023 Jan 23. doi: 10.1007/s12282-023-01436.
    PubMed     Abstract available


  211. LI Y, Na F, Pei J
    Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification.
    Breast Cancer. 2023 Jan 20. doi: 10.1007/s12282-023-01434.
    PubMed     Abstract available


  212. COLLET L, Eberst L, Ludovic G, Debled M, et al
    Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
    Breast Cancer. 2023 Jan 11. doi: 10.1007/s12282-022-01427.
    PubMed     Abstract available


  213. HASAN MT, Hamouda M, Khashab MKE, Elsnhory AB, et al
    Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients.
    Breast Cancer. 2023 Jan 9. doi: 10.1007/s12282-022-01430.
    PubMed     Abstract available


  214. MA J, Wang F, Chen C, Ji J, et al
    Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer.
    Breast Cancer. 2023 Jan 9. doi: 10.1007/s12282-023-01433.
    PubMed     Abstract available


  215. FUTAMURA M, Ishihara K, Nagao Y, Ogiso A, et al
    Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
    Breast Cancer. 2023 Jan 7. doi: 10.1007/s12282-022-01425.
    PubMed     Abstract available


  216. BAILLEUX C, Arnaud A, Frenel JS, Chabaud S, et al
    CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
    Breast Cancer. 2023 Jan 5. doi: 10.1007/s12282-022-01426.
    PubMed     Abstract available


  217. OCHI T, Yoshida A, Takahashi O, Kajiura Y, et al
    Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis.
    Breast Cancer. 2023 Jan 3. doi: 10.1007/s12282-022-01429.
    PubMed     Abstract available


  218. OHSUMI S, Nishimura R, Masuda N, Akashi-Tanaka S, et al
    A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy.
    Breast Cancer. 2023;30:131-138.
    PubMed     Abstract available


  219. OHNEDA K, Hamanaka Y, Kawame H, Fuse N, et al
    Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
    Breast Cancer. 2023;30:110-120.
    PubMed     Abstract available


  220. UEMATSU T, Nakashima K, Harada TL, Nasu H, et al
    Artificial intelligence computer-aided detection enhances synthesized mammograms: comparison with original digital mammograms alone and in combination with tomosynthesis images in an experimental setting.
    Breast Cancer. 2023;30:46-55.
    PubMed     Abstract available


    December 2022
  221. ANUSZKIEWICZ K, Jankau J, Kur M
    What do we know about treating breast-cancer-related lymphedema? Review of the current knowledge about therapeutic options.
    Breast Cancer. 2022 Dec 26. doi: 10.1007/s12282-022-01428.
    PubMed     Abstract available


  222. TAJI T, Odan N, Kataoka Y, Ikeda M, et al
    Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.
    Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01424.
    PubMed     Abstract available


  223. TADA K, Kumamaru H, Miyata H, Asaga S, et al
    Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018.
    Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01423.
    PubMed     Abstract available


  224. MANFUKU M, Nishigami T, Mibu A, Yamashita H, et al
    Predictors of persistent post-surgical pain intensity and interference at 1 year after breast cancer surgery: assessing central sensitization, central sensitivity symptoms, and psychological factors.
    Breast Cancer. 2022 Dec 18. doi: 10.1007/s12282-022-01420.
    PubMed     Abstract available


  225. KAWAMOTO T, Shikama N, Imano N, Kubota H, et al
    Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
    Breast Cancer. 2022 Dec 17. doi: 10.1007/s12282-022-01422.
    PubMed     Abstract available


  226. CHU J, Min KW, Kim DH, Son BK, et al
    High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach.
    Breast Cancer. 2022 Dec 7. doi: 10.1007/s12282-022-01419.
    PubMed     Abstract available


  227. WATZEK JT, Gordon LG, Sandler CX, Spence RR, et al
    A cost-consequences analysis of the SAFE trial: a comparative, effectiveness trial evaluating high- versus low-supervision of an exercise intervention for women with breast cancer.
    Breast Cancer. 2022 Dec 3. doi: 10.1007/s12282-022-01418.
    PubMed     Abstract available


    November 2022
  228. NGUYEN HM, Paulishak W, Oladejo M, Wood L, et al
    Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches.
    Breast Cancer. 2022 Nov 18. pii: 10.1007/s12282-022-01415.
    PubMed     Abstract available


  229. SEKIGUCHI K, Sumi M, Saito A, Zenda S, et al
    Correction to: The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 Nov 17. pii: 10.1007/s12282-022-01416.
    PubMed    


  230. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    Conservative axillary surgery is emerging in the surgical management of breast cancer.
    Breast Cancer. 2022 Nov 7. pii: 10.1007/s12282-022-01409.
    PubMed     Abstract available


  231. SHIRAISHI M, Sowa Y, Tsuge I, Shiraishi A, et al
    Risk factors associated with chronic pain after mastectomy: a prospective study with a 5-year follow-up in Japan.
    Breast Cancer. 2022;29:1133-1139.
    PubMed     Abstract available


  232. KARAKAWA R, Konishi T, Yoshimatsu H, Fuse Y, et al
    Comparison of short-term outcomes between pedicled- and free-flap autologous breast reconstruction: a nationwide inpatient database study in Japan.
    Breast Cancer. 2022;29:1067-1075.
    PubMed     Abstract available


  233. ALAM B, Akbari AR, Alali B, Thankan E, et al
    Antibiotic prophylaxis in breast surgery: a meta-analysis to identify the optimal strategy to reduce infection rates in breast surgery.
    Breast Cancer. 2022;29:945-956.
    PubMed     Abstract available


  234. MUSTAFA ALI MK, Samhouri Y, Law JY, Khan C, et al
    Patterns of treatment and their outcomes in primary breast lymphoma; a comprehensive population-based analysis.
    Breast Cancer. 2022;29:1022-1031.
    PubMed     Abstract available


  235. HASHIMOTO R, Akashi-Tanaka S, Watanabe C, Masuda H, et al
    Diagnostic performance of dedicated breast positron emission tomography.
    Breast Cancer. 2022;29:1013-1021.
    PubMed     Abstract available


  236. BAILEY S, Ezratty C, Mhango G, Lin JJ, et al
    Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors.
    Breast Cancer. 2022 Nov 1. pii: 10.1007/s12282-022-01411.
    PubMed     Abstract available


    October 2022
  237. SUZUKI K, Sasada S, Nishi H, Kimura Y, et al
    Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.
    Breast Cancer. 2022 Oct 21. pii: 10.1007/s12282-022-01410.
    PubMed     Abstract available


  238. SEKIGUCHI K, Sumi M, Saito A, Zenda S, et al
    The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 Oct 18. pii: 10.1007/s12282-022-01403.
    PubMed     Abstract available


  239. MAVROPALIAS G, Cormie P, Peddle-McIntyre CJ, Galvao DA, et al
    The effects of home-based exercise therapy for breast cancer-related fatigue induced by radical radiotherapy.
    Breast Cancer. 2022 Oct 14. pii: 10.1007/s12282-022-01408.
    PubMed     Abstract available


    September 2022
  240. COLOMBAGE UN, Soh SE, Lin KY, Kruger J, et al
    The feasibility of pelvic floor training to treat urinary incontinence in women with breast cancer: a telehealth intervention trial.
    Breast Cancer. 2022 Sep 26. pii: 10.1007/s12282-022-01405.
    PubMed     Abstract available


  241. LIAO N, Li C, Cao L, Chen Y, et al
    Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node.
    Breast Cancer. 2022 Sep 21. pii: 10.1007/s12282-022-01400.
    PubMed     Abstract available


  242. YANG ZY, Yin SP, Ren Q, Lu DW, et al
    Correction to: BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion.
    Breast Cancer. 2022 Sep 16. pii: 10.1007/s12282-022-01402.
    PubMed    


  243. MANSFIELD C, Botha W, Vondeling GT, Klein K, et al
    Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
    Breast Cancer. 2022 Sep 8. pii: 10.1007/s12282-022-01394.
    PubMed     Abstract available


  244. ALEIXO GFP, Valente SA, Wei W, Chen PH, et al
    Sarcopenia detected with bioelectrical impedance versus CT scan and chemotherapy tolerance in patients with early breast cancer.
    Breast Cancer. 2022 Sep 5. pii: 10.1007/s12282-022-01401.
    PubMed     Abstract available


  245. YAMAMOTO Y, Yamashiro H, Schneeweiss A, Muller V, et al
    Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational stu
    Breast Cancer. 2022 Sep 3. pii: 10.1007/s12282-022-01399.
    PubMed     Abstract available


  246. JUNG J, Hwang KT, Choi IS, Kim BH, et al
    Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database.
    Breast Cancer. 2022;29:889-898.
    PubMed     Abstract available


  247. UEMATSU T
    Sensitivity and specificity of screening mammography without clinical breast examination among Japanese women aged 40-49 years: analysis of data from the J-START results.
    Breast Cancer. 2022;29:928-931.
    PubMed     Abstract available


  248. WOO JW, Choi HY, Kim M, Chung YR, et al
    miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
    Breast Cancer. 2022;29:814-824.
    PubMed     Abstract available


    August 2022
  249. NGAN TT, Browne S, Goodwin M, Van Minh H, et al
    Cost-effectiveness of clinical breast examination screening programme among HER2-positive breast cancer patients: a modelling study.
    Breast Cancer. 2022 Aug 26. pii: 10.1007/s12282-022-01398.
    PubMed     Abstract available


  250. CINAR V, Hamurcu Z, Guler A, Nurdinov N, et al
    Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Breast Cancer. 2022 Aug 25. pii: 10.1007/s12282-022-01391.
    PubMed     Abstract available


  251. KONISHI T, Tanabe M, Michihata N, Matsui H, et al
    Risk factors for arm lymphedema following breast cancer surgery: a Japanese nationwide database study of 84,022 patients.
    Breast Cancer. 2022 Aug 23. pii: 10.1007/s12282-022-01395.
    PubMed     Abstract available


  252. ZHU Y, Iwamoto T, Kajiwara Y, Takahashi Y, et al
    Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.
    Breast Cancer. 2022 Aug 22. pii: 10.1007/s12282-022-01397.
    PubMed     Abstract available


  253. HAJI GHAFFARI M, Simonian M, Salimi A, Mirzadegan E, et al
    A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer.
    Breast Cancer. 2022 Aug 18. pii: 10.1007/s12282-022-01393.
    PubMed     Abstract available


    July 2022
  254. KOTANI H, Masuda N, Yamashita T, Naito Y, et al
    Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    Breast Cancer. 2022 Jul 30. pii: 10.1007/s12282-022-01390.
    PubMed     Abstract available


  255. ZHU J, Wu W, Togashi Y, Taira Nihira N, et al
    Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
    Breast Cancer. 2022 Jul 27. pii: 10.1007/s12282-022-01389.
    PubMed     Abstract available


  256. MOTALEBZADEH J, Eskandari E
    Comprehensive analysis of DRAIC and TP53TG1 in breast cancer luminal subtypes through the construction of lncRNAs regulatory model.
    Breast Cancer. 2022 Jul 24. pii: 10.1007/s12282-022-01385.
    PubMed     Abstract available


  257. NOZAKI M, Kagami Y, Takahashi M, Machida R, et al
    Evaluation of breast cosmetic changes with a computer-software; the breast cancer conservative treatment cosmetic results (BCCT. core) in hypofractionated whole breast irradiation after breast-conserving surgery-supplementary analysis of multicenter s
    Breast Cancer. 2022 Jul 21. pii: 10.1007/s12282-022-01384.
    PubMed     Abstract available


  258. WOOD KC, Hidde M, Kendig T, Pergolotti M, et al
    Community-based outpatient rehabilitation for the treatment of breast cancer-related upper extremity disability: an evaluation of practice-based evidence.
    Breast Cancer. 2022 Jul 21. pii: 10.1007/s12282-022-01388.
    PubMed     Abstract available


  259. NAMBA T, Matsuda N, Rahman M, Kanomata N, et al
    Association between mammographic breast composition and breast cancer risk among Japanese women: a retrospective cohort study.
    Breast Cancer. 2022 Jul 13. pii: 10.1007/s12282-022-01376.
    PubMed     Abstract available


  260. NOURI-MAJD S, Salari-Moghaddam A, Benisi-Kohansal S, Azadbakht L, et al
    Dietary intake of branched-chain amino acids in relation to the risk of breast cancer.
    Breast Cancer. 2022 Jul 6. pii: 10.1007/s12282-022-01379.
    PubMed     Abstract available


  261. HAN R, Yang H, Ling C, Lu L, et al
    Neurospora crassa is a potential source of anti-cancer agents against breast cancer.
    Breast Cancer. 2022 Jul 5. pii: 10.1007/s12282-022-01383.
    PubMed     Abstract available


  262. TSUDA H, Kurosumi M, Akiyama F, Ohno S, et al
    Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N.SAS-BC 01 trial.
    Breast Cancer. 2022;29:720-729.
    PubMed     Abstract available


  263. YOSHIDA K, Nose T, Otani Y, Asahi S, et al
    A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using multicatheter interstitial brachytherapy: clinical results with a median follow-up of 60 months.
    Breast Cancer. 2022;29:636-644.
    PubMed     Abstract available


  264. NAKAYAMA S, Masuda H, Miura S, Kuwayama T, et al
    Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma.
    Breast Cancer. 2022;29:610-617.
    PubMed     Abstract available


  265. HAYASHI S, Kubo M, Kaneshiro K, Kai M, et al
    Genetic medicine is accelerating in Japan.
    Breast Cancer. 2022;29:659-665.
    PubMed     Abstract available


  266. GANDOMKAR Z, Lewis SJ, Li T, Ekpo EU, et al
    A machine learning model based on readers' characteristics to predict their performances in reading screening mammograms.
    Breast Cancer. 2022;29:589-598.
    PubMed     Abstract available


    June 2022
  267. DANG LA, Chazard E, Poncelet E, Serb T, et al
    Impact of artificial intelligence in breast cancer screening with mammography.
    Breast Cancer. 2022 Jun 28. pii: 10.1007/s12282-022-01375.
    PubMed     Abstract available


  268. WAGONER CW, Lee JT, Hanson ED, Kerr ZY, et al
    Impact of community-based exercise on fatigue in early breast cancer survivors: identifying potential determinants of change.
    Breast Cancer. 2022 Jun 24. pii: 10.1007/s12282-022-01380.
    PubMed     Abstract available


  269. WANG W, Qiu P, Li J
    Internal mammary lymph node metastasis in breast cancer patients based on anatomical imaging and functional imaging.
    Breast Cancer. 2022 Jun 24. pii: 10.1007/s12282-022-01377.
    PubMed     Abstract available


  270. SHIMOMURA A, Nagahashi M, Kumamaru H, Aogi K, et al
    Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.
    Breast Cancer. 2022 Jun 22. pii: 10.1007/s12282-022-01378.
    PubMed     Abstract available


  271. CHEN M, Chen W, Liu D, Chen W, et al
    Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer.
    Breast Cancer. 2022 Jun 21. pii: 10.1007/s12282-022-01364.
    PubMed     Abstract available


  272. ZHANG X, Zhao X, Chang L, Liu F, et al
    LncRNA FOXD3-AS1 promotes breast cancer progression by mediating ARF6.
    Breast Cancer. 2022 Jun 9. pii: 10.1007/s12282-022-01373.
    PubMed     Abstract available


  273. LI Q, Lesseur C, Neugut AI, Santella RM, et al
    The associations of healthy lifestyle index with breast cancer incidence and mortality in a population-based study.
    Breast Cancer. 2022 Jun 3. pii: 10.1007/s12282-022-01374.
    PubMed     Abstract available


  274. VAZEH H, Behboudi E, Hashemzadeh-Omran A, Moradi A, et al
    Live-attenuated poliovirus-induced extrinsic apoptosis through Caspase 8 within breast cancer cell lines expressing CD155.
    Breast Cancer. 2022 Jun 1. pii: 10.1007/s12282-022-01372.
    PubMed     Abstract available


    May 2022
  275. MINOURA Y, Takahashi M, Maeda H, Kuwahara S, et al
    Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
    Breast Cancer. 2022 May 31. pii: 10.1007/s12282-022-01360.
    PubMed     Abstract available


  276. KATAOKA A, Ueno T, Yamauchi H, Uehiro N, et al
    Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC).
    Breast Cancer. 2022 May 23. pii: 10.1007/s12282-022-01362.
    PubMed     Abstract available


  277. LIN SQ, Su CM, Wu HC, Chou YY, et al
    Effect of patient decision aids on decisional conflict and regret associated with breast cancer surgery: a randomized controlled trial.
    Breast Cancer. 2022 May 19. pii: 10.1007/s12282-022-01370.
    PubMed     Abstract available


  278. BAN K, Tsunoda H, Togashi S, Kawakami M, et al
    Comparative study of the usefulness of adjunctive tomosynthesis in breast cancer screening by mammography and ultrasound in Japan.
    Breast Cancer. 2022 May 18. pii: 10.1007/s12282-022-01358.
    PubMed     Abstract available


  279. KHODABANDEH Z, Valilo M, Velaei K, Pirpour Tazehkand A, et al
    The potential role of nicotine in breast cancer initiation, development, angiogenesis, invasion, metastasis, and resistance to therapy.
    Breast Cancer. 2022 May 18. pii: 10.1007/s12282-022-01369.
    PubMed     Abstract available


  280. PANG Y, Wei Y, Kartsonaki C
    Associations of adiposity and weight change with recurrence and survival in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 May 17. pii: 10.1007/s12282-022-01355.
    PubMed     Abstract available


  281. ROY P, Sur S, Das S, Wui WT, et al
    Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer: a comprehensive update.
    Breast Cancer. 2022 May 16. pii: 10.1007/s12282-022-01368.
    PubMed     Abstract available


  282. PARK JK, Seo J, Yang EJ, Kang Y, et al
    Association of lymphatic flow velocity with surgical outcomes in patients undergoing lymphovenous anastomosis for breast cancer-related lymphedema.
    Breast Cancer. 2022 May 12. pii: 10.1007/s12282-022-01363.
    PubMed     Abstract available


  283. LI X, Wang Y, Zhang Y, Liu B, et al
    Overexpression of MCAM induced by SMYD2-H3K36me2 in breast cancer stem cell properties.
    Breast Cancer. 2022 May 12. pii: 10.1007/s12282-022-01365.
    PubMed     Abstract available


  284. HO PJ, Khng AJ, Tan BK, Tan EY, et al
    Relevance of the MHC region for breast cancer susceptibility in Asians.
    Breast Cancer. 2022 May 11. pii: 10.1007/s12282-022-01366.
    PubMed     Abstract available


  285. RUIDAS B, Sur TK, Das Mukhopadhyay C, Sinha K, et al
    Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1.
    Breast Cancer. 2022 May 5. pii: 10.1007/s12282-022-01356.
    PubMed     Abstract available


  286. NARA M, Ishihara S, Kitano A, Tamura N, et al
    Does breast-conserving surgery with radiotherapy in BRCA-mutation carriers significantly increase ipsilateral breast tumor recurrence? A systematic review and meta-analysis.
    Breast Cancer. 2022;29:394-401.
    PubMed     Abstract available


  287. HIRATA M, Toda H, Higo N, Shinden Y, et al
    Modification of oncoplastic breast surgery with immediate volume replacement using a thoracodorsal adipofascial flap.
    Breast Cancer. 2022;29:531-540.
    PubMed     Abstract available


  288. NASIF D, Real S, Roque M, Branham MT, et al
    CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.
    Breast Cancer. 2022;29:562-573.
    PubMed     Abstract available


  289. GRUNTKEMEIER L, Khurana A, Bischoff FZ, Hoffmann O, et al
    Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray-HER2-FISH workflow.
    Breast Cancer. 2022;29:487-497.
    PubMed     Abstract available


  290. GAO P, Wang X, Bai P, Kong X, et al
    Clinical outcomes and patient satisfaction with the use of biological and synthetic meshes in one-stage implant-based breast reconstruction.
    Breast Cancer. 2022;29:450-457.
    PubMed     Abstract available


    April 2022
  291. MONSIVAIS P, Amiri S, Robison J, Pflugeisen C, et al
    Correction to: Racial and socioeconomic inequities in breast cancer screening before and during the COVID-19 pandemic: analysis of two cohorts of women 50 years + .
    Breast Cancer. 2022 Apr 30. pii: 10.1007/s12282-022-01361.
    PubMed    


  292. KIKAWA Y, Kotake T, Tsuyuki S, Kang Y, et al
    Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
    Breast Cancer. 2022 Apr 23. pii: 10.1007/s12282-022-01357.
    PubMed     Abstract available


  293. BLATNIK A, Ribnikar D, Setrajcic Dragos V, Novakovic S, et al
    BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome.
    Breast Cancer. 2022 Apr 5. pii: 10.1007/s12282-022-01354.
    PubMed     Abstract available


  294. MONSIVAIS P, Amiri S, Robison J, Pflugeisen C, et al
    Racial and socioeconomic inequities in breast cancer screening before and during the COVID-19 pandemic: analysis of two cohorts of women 50 years + .
    Breast Cancer. 2022 Apr 2. pii: 10.1007/s12282-022-01352.
    PubMed     Abstract available


    March 2022
  295. HENG YJ, Love S, DeHart JC, Fingeroth JD, et al
    The association of infectious mononucleosis and invasive breast cancer in The Health of Women (HOW) Study((R)).
    Breast Cancer. 2022 Mar 26. pii: 10.1007/s12282-022-01351.
    PubMed     Abstract available


  296. TERADA M, Miyashita M, Kumamaru H, Miyata H, et al
    Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry.
    Breast Cancer. 2022 Mar 22. pii: 10.1007/s12282-022-01348.
    PubMed     Abstract available


  297. PINTO CS, Peleteiro B, Pinto CA, Osorio F, et al
    Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
    Breast Cancer. 2022 Mar 19. pii: 10.1007/s12282-022-01349.
    PubMed     Abstract available


  298. FICARRA S, Thomas E, Bianco A, Gentile A, et al
    Impact of exercise interventions on physical fitness in breast cancer patients and survivors: a systematic review.
    Breast Cancer. 2022 Mar 12. pii: 10.1007/s12282-022-01347.
    PubMed     Abstract available


  299. JUNJUN S, Yangyanqiu W, Jing Z, Jie P, et al
    Prognostic model based on six PD-1 expression and immune infiltration-associated genes predicts survival in breast cancer.
    Breast Cancer. 2022 Mar 1. pii: 10.1007/s12282-022-01344.
    PubMed     Abstract available


  300. JAMSHIDI F, Farzad M, MacDermid JC, Varahra A, et al
    Assessing the content based on ICF and quality based on COSMIN criteria of patient-reported outcome measures of functioning in breast cancer survivors: a systematic review.
    Breast Cancer. 2022 Mar 1. pii: 10.1007/s12282-022-01340.
    PubMed     Abstract available


  301. OKAZAKI M, Muguruma M, Komiya T, Miyahara K, et al
    Beneficial effects of transdermal administration of tamoxifen on capsular contracture after breast implantation in murine models.
    Breast Cancer. 2022;29:343-351.
    PubMed     Abstract available


  302. ZELLINGER B, Bodenhofer U, Englander IA, Kronberger C, et al
    Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.
    Breast Cancer. 2022;29:274-286.
    PubMed     Abstract available


  303. BERNINI M, Meattini I, Saieva C, Becherini C, et al
    Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy.
    Breast Cancer. 2022;29:302-313.
    PubMed     Abstract available


  304. FAULKNER HR, Coopey SB, Liao EC, Specht M, et al
    The safety of performing breast reconstruction during the COVID-19 pandemic.
    Breast Cancer. 2022;29:242-246.
    PubMed     Abstract available


    February 2022
  305. YUEN S, Monzawa S, Gose A, Yanai S, et al
    Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer: comparison with contrast-enhanced breast MRI.
    Breast Cancer. 2022 Feb 26. pii: 10.1007/s12282-022-01345.
    PubMed     Abstract available


  306. KONISHI T, Fujiogi M, Michihata N, Kumazawa R, et al
    Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan.
    Breast Cancer. 2022 Feb 26. pii: 10.1007/s12282-022-01346.
    PubMed     Abstract available


  307. LEINERT E, Schwentner L, Janni W, Wockel A, et al
    Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
    Breast Cancer. 2022 Feb 18. pii: 10.1007/s12282-021-01321.
    PubMed     Abstract available


  308. YUAN B, Liu W, Huo M, Zhang J, et al
    The hub ten gene-based risk score system using RNA m(6)A methylation regulator features and tumor immune microenvironment in breast cancer.
    Breast Cancer. 2022 Feb 16. pii: 10.1007/s12282-022-01341.
    PubMed     Abstract available


  309. LOPEZ C, Bosch R, Korzynska A, Garcia-Rojo M, et al
    CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.
    Breast Cancer. 2022 Feb 8. pii: 10.1007/s12282-022-01336.
    PubMed     Abstract available


  310. DIEHM YF, Marstaller K, Seckler AM, Berger MR, et al
    The collagenase of the bacterium Clostridium histolyticum does not favor metastasis of breast cancer.
    Breast Cancer. 2022 Feb 7. pii: 10.1007/s12282-022-01337.
    PubMed     Abstract available


    January 2022
  311. ZAREIE B, Rasouli MA, Poorolajal J
    Risk of primary lung cancer after breast cancer radiotherapy: a systematic review and meta-analysis.
    Breast Cancer. 2022 Jan 28. pii: 10.1007/s12282-021-01318.
    PubMed     Abstract available


  312. DASHTI F, Soltani S, Benisi-Kohansal S, Azadbakht L, et al
    Consumption of dairy products and odds of breast cancer: an Iranian case-control study.
    Breast Cancer. 2022 Jan 27. pii: 10.1007/s12282-021-01317.
    PubMed     Abstract available


  313. YANG A, Wu M, Ni M, Zhang L, et al
    A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.
    Breast Cancer. 2022 Jan 21. pii: 10.1007/s12282-021-01326.
    PubMed     Abstract available


  314. YANG ZY, Yin SP, Ren Q, Lu DW, et al
    BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion.
    Breast Cancer. 2022 Jan 19. pii: 10.1007/s12282-022-01333.
    PubMed     Abstract available


  315. ZENG Q, Lin X, Chen H, Yan Y, et al
    Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.
    Breast Cancer. 2022 Jan 18. pii: 10.1007/s12282-021-01325.
    PubMed     Abstract available


  316. GU JH, He C, Zhao QY, Jiang TA, et al
    Usefulness of new shear wave elastography in early predicting the efficacy of neoadjuvant chemotherapy for patients with breast cancer: where and when to measure is optimal?
    Breast Cancer. 2022 Jan 17. pii: 10.1007/s12282-021-01327.
    PubMed     Abstract available


  317. MORITA M, Shimomura A, Tokuda E, Horimoto Y, et al
    Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Breast Cancer. 2022 Jan 15. pii: 10.1007/s12282-021-01329.
    PubMed     Abstract available


  318. CARRETTI G, Mirandola D, Maestrini F, Sequi L, et al
    Quality of life improvement in breast cancer survivors affected by upper limb lymphedema through a novel multiperspective physical activity methodology: a monocentric pilot study.
    Breast Cancer. 2022 Jan 13. pii: 10.1007/s12282-021-01322.
    PubMed     Abstract available


  319. UDDIN MN, Wang X
    Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer.
    Breast Cancer. 2022 Jan 12. pii: 10.1007/s12282-022-01332.
    PubMed     Abstract available


  320. ABDELRAZEK MA, Nageb A, Barakat LA, Abouzid A, et al
    BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
    Breast Cancer. 2022 Jan 7. pii: 10.1007/s12282-021-01328.
    PubMed     Abstract available


  321. HAILEY V, Rojas-Garcia A, Kassianos AP
    A systematic review of behaviour change techniques used in interventions to increase physical activity among breast cancer survivors.
    Breast Cancer. 2022 Jan 6. pii: 10.1007/s12282-021-01323.
    PubMed     Abstract available


  322. NIMBI FM, Magno S, Agostini L, Di Micco A, et al
    Sexuality in breast cancer survivors: sexual experiences, emotions, and cognitions in a group of women under hormonal therapy.
    Breast Cancer. 2022 Jan 6. pii: 10.1007/s12282-021-01320.
    PubMed     Abstract available


  323. SUETA A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, et al
    Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    Breast Cancer. 2022 Jan 5. pii: 10.1007/s12282-021-01319.
    PubMed     Abstract available


    November 2021
  324. SU SY
    Nationwide mammographic screening and breast cancer mortality in Taiwan: an interrupted time-series analysis.
    Breast Cancer. 2021 Nov 26. pii: 10.1007/s12282-021-01315.
    PubMed     Abstract available


  325. MUKAND NH, Ko NY, Nabulsi NA, Hubbard CC, et al
    The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women.
    Breast Cancer. 2021 Nov 19. pii: 10.1007/s12282-021-01309.
    PubMed     Abstract available


  326. EVANS A, Sim YT, Lawson B, Macaskill J, et al
    The value of prognostic ultrasound features of breast cancer in different molecular subtypes with a focus on triple negative disease.
    Breast Cancer. 2021 Nov 15. pii: 10.1007/s12282-021-01311.
    PubMed     Abstract available


  327. VAN EGDOM LSE, de Ligt KM, de Munck L, Koppert LB, et al
    Predictors of delayed breast reconstruction in the Netherlands: a 5-year follow-up study in stage I-III breast cancer patients.
    Breast Cancer. 2021 Nov 15. pii: 10.1007/s12282-021-01313.
    PubMed     Abstract available


  328. WANG C, Lin Y, Zhu H, Zhou Y, et al
    Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
    Breast Cancer. 2021 Nov 11. pii: 10.1007/s12282-021-01312.
    PubMed     Abstract available


  329. MAROUFI NF, Rashidi M, Vahedian V, Jahanbazi R, et al
    Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line.
    Breast Cancer. 2021 Nov 1. pii: 10.1007/s12282-021-01310.
    PubMed     Abstract available


  330. LI X, Lin M, Xu J, Pang Y, et al
    New variant of breast-invasive lobular carcinoma with solid and encapsulated papillary carcinoma growth pattern.
    Breast Cancer. 2021;28:1383-1388.
    PubMed     Abstract available


  331. KOTOULA V, Papadopoulou K, Tikas I, Fostira F, et al
    Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    Breast Cancer. 2021;28:1367-1382.
    PubMed     Abstract available


  332. TANG X, Nakanishi Y, Kobayashi H, Nishimaki H, et al
    Mixed ductal-lobular carcinoma: an analysis of CDH1 DNA copy number variation and mutation.
    Breast Cancer. 2021;28:1318-1327.
    PubMed     Abstract available


  333. SIEGWART LC, Fischer S, Diehm YF, Heil JM, et al
    The transverse musculocutaneous gracilis flap for autologous breast reconstruction: focus on donor site morbidity.
    Breast Cancer. 2021;28:1273-1282.
    PubMed     Abstract available


  334. YOSHIDA R
    Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
    Breast Cancer. 2021;28:1167-1180.
    PubMed     Abstract available


  335. TAKAHAMA N, Tozaki M, Ohgiya Y
    Current status of MRI-guided vacuum-assisted breast biopsy in Japan.
    Breast Cancer. 2021;28:1188-1194.
    PubMed     Abstract available


  336. TOZAKI M, Nakamura S
    Current status of breast cancer screening in high-risk women in Japan.
    Breast Cancer. 2021;28:1181-1187.
    PubMed     Abstract available


    October 2021
  337. VEGUNTA S, Bhatt AA, Choudhery SA, Pruthi S, et al
    Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging.
    Breast Cancer. 2021 Oct 19. pii: 10.1007/s12282-021-01298.
    PubMed     Abstract available


  338. YOTSUMOTO D, Sagara Y, Kumamaru H, Niikura N, et al
    Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan.
    Breast Cancer. 2021 Oct 19. pii: 10.1007/s12282-021-01307.
    PubMed     Abstract available


  339. TAKAHASHI M, Tokunaga E, Mori J, Tanizawa Y, et al
    Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Breast Cancer. 2021 Oct 18. pii: 10.1007/s12282-021-01295.
    PubMed     Abstract available


  340. ROBERTS S, Rojas A, DiRaimo G, Orlando M, et al
    Defer surgery in operable breast cancer: how long is too long?
    Breast Cancer. 2021 Oct 18. pii: 10.1007/s12282-021-01302.
    PubMed     Abstract available


  341. DIAZ-ROLDAN J, Eguia-Larrea M, Rubio-Sanchez T, Munoz-Bellvis L, et al
    Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease?
    Breast Cancer. 2021 Oct 15. pii: 10.1007/s12282-021-01293.
    PubMed     Abstract available


  342. OZAKI A, Tachibana K, Ohtake T
    Correction to: Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Toho
    Breast Cancer. 2021 Oct 13. pii: 10.1007/s12282-021-01306.
    PubMed    


  343. LI B, Cheng X, Zhu Y, Wan H, et al
    FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population.
    Breast Cancer. 2021 Oct 11. pii: 10.1007/s12282-021-01305.
    PubMed     Abstract available


  344. LEBOK P, Bonte H, Kluth M, Moller-Koop C, et al
    6q deletion is frequent but unrelated to patient prognosis in breast cancer.
    Breast Cancer. 2021 Oct 8. pii: 10.1007/s12282-021-01301.
    PubMed     Abstract available


  345. HORISAWA N, Adachi Y, Takatsuka D, Nozawa K, et al
    The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status.
    Breast Cancer. 2021 Oct 7. pii: 10.1007/s12282-021-01303.
    PubMed     Abstract available


    September 2021
  346. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
    Breast Cancer. 2021 Sep 30. pii: 10.1007/s12282-021-01300.
    PubMed     Abstract available


  347. TAIRA N, Kashiwabara K, Tsurutani J, Kitada M, et al
    Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01296.
    PubMed    


  348. KOH SJ, Ohsumi S, Takahashi M, Fukuma E, et al
    Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analys
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01299.
    PubMed    


  349. MORI N, Abe H, Mugikura S, Miyashita M, et al
    Discriminating low-grade ductal carcinoma in situ (DCIS) from non-low-grade DCIS or DCIS upgraded to invasive carcinoma: effective texture features on ultrafast dynamic contrast-enhanced magnetic resonance imaging.
    Breast Cancer. 2021;28:1141-1153.
    PubMed     Abstract available


  350. NAKASHIMA K, Uematsu T, Harada TL, Takahashi K, et al
    Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?
    Breast Cancer. 2021;28:1120-1130.
    PubMed     Abstract available


    July 2021
  351. MINEMURA H, Takagi K, Sato A, Yamaguchi M, et al
    Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
    Breast Cancer. 2021;28:915-926.
    PubMed     Abstract available


  352. TOZAKI M, Yabuuchi H, Goto M, Sasaki M, et al
    Effects of gadobutrol on background parenchymal enhancement and differential diagnosis between benign and malignant lesions in dynamic magnetic resonance imaging of the breast.
    Breast Cancer. 2021;28:927-936.
    PubMed     Abstract available


  353. TENG X, Hayashida T, Murata T, Nagayama A, et al
    A transposon screen identifies enhancement of NF-kappaB pathway as a mechanism of resistance to eribulin.
    Breast Cancer. 2021;28:884-895.
    PubMed     Abstract available


  354. TANAKA K, Masuda N, Hayashi N, Sagara Y, et al
    Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
    Breast Cancer. 2021;28:896-903.
    PubMed     Abstract available


  355. XU C, Gu Z, Liu J, Lin X, et al
    Adenosquamous carcinoma of the breast: a population-based study.
    Breast Cancer. 2021;28:848-858.
    PubMed     Abstract available


    May 2021
  356. MEHRAJ U, Qayoom H, Mir MA
    Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.
    Breast Cancer. 2021;28:539-555.
    PubMed     Abstract available


  357. AKASHI M, Yamaguchi R, Kusano H, Yamaguchi M, et al
    ER staining levels affect HER2 staining and heterogeneity.
    Breast Cancer. 2021;28:720-726.
    PubMed     Abstract available


  358. ZHANG R, Gao P, Han Y, Zhang R, et al
    Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study.
    Breast Cancer. 2021;28:672-683.
    PubMed     Abstract available


  359. JIA M, Liao N, Chen B, Zhang G, et al
    PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Breast Cancer. 2021;28:644-652.
    PubMed     Abstract available


    March 2021
  360. MCMULLEN ER, Skala SL, Gonzalez ME, Djomehri S, et al
    Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
    Breast Cancer. 2021;28:496-505.
    PubMed     Abstract available


  361. MAEDA H, Hayashida T, Watanuki R, Kikuchi M, et al
    Predictors of invasive disease in patients preoperatively diagnosed with ductal carcinoma without stromal invasion, with breast magnetic resonance imaging (MRI) and ultrasound (US).
    Breast Cancer. 2021;28:398-404.
    PubMed     Abstract available


  362. CORADINI D, Gambazza S, Oriana S, Ambrogi F, et al
    Gene expression profile of normal breast tissue and body mass index.
    Breast Cancer. 2021;28:488-495.
    PubMed     Abstract available


  363. FILIPE MD, Simons JM, Moeliker L, Waaijer L, et al
    Patient-reported outcomes of ductoscopy procedures for pathologic nipple discharge.
    Breast Cancer. 2021;28:471-477.
    PubMed     Abstract available


  364. VERDE F, Vigliar E, Romeo V, Campanino MR, et al
    Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): a challenging cytological diagnosis with hybrid PET/MRI staging and follow-up.
    Breast Cancer. 2021;28:527-532.
    PubMed     Abstract available


  365. KUMARI K, Kumar S, Parida DK, Mishra SK, et al
    EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.
    Breast Cancer. 2021;28:355-367.
    PubMed     Abstract available


  366. GLASGOW A, Sechrist H, Bomeisl P, Gilmore H, et al
    Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Breast Cancer. 2021;28:321-328.
    PubMed     Abstract available


  367. CARRARA GFA, Evangelista AF, Scapulatempo-Neto C, Abrahao-Machado LF, et al
    Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival.
    Breast Cancer. 2021;28:307-320.
    PubMed     Abstract available


  368. ZHAO JM, An Q, Sun CN, Li YB, et al
    Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
    Breast Cancer. 2021;28:298-306.
    PubMed     Abstract available


  369. VUKSANOVIC D, Sanmugarajah J, Lunn D, Sawhney R, et al
    Unmet needs in breast cancer survivors are common, and multidisciplinary care is underutilised: the Survivorship Needs Assessment Project.
    Breast Cancer. 2021;28:289-297.
    PubMed     Abstract available


  370. ALATAWI Y, Hansen RA, Chou C, Qian J, et al
    The impact of cognitive impairment on survival and medication adherence among older women with breast cancer.
    Breast Cancer. 2021;28:277-288.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.